RegMed Forum “The multifaceted potential of CRISPR-Cas9 in medicine”
Please note: The current Corona regulations and quarantine rules as well as the 2G rule apply to this on-site event (see here and below for more information).
We strongly encourage everyone to perform a point-of-care (PoC) antigen test before the event.
The disruptive potential of CRISPR-Cas9 was crystal clear from the very first publication on the subject. Since then, the diversity of possible uses has exploded. The feasibility and subsequent translation into real world applications in the medical field has proceeded at an unprecedented speed.
In this year’s RegMed forum on November 25th 2021 in Berlin, Germany, academic researchers and industry scientists will shed light on the potential of CRISPR-Cas9 in medicine and will share their scientific findings and clinical experiences using the CRISPR-Cas9 technology.
Confirmed speakers:
- Leila Amini - BCRT & BeCAT
- Andre Cohnen - Bayer AG
- Juergen Foell - University of Regensburg
- Michael Kaminski - MDC & Charité
- Manuel Kaulich - Goethe University Frankfurt am Main & Vivlion GmbH
- Simone Spuler - MDC & Charité
- Dimitrios Wagner - BCRT & BeCAT
This year, the opportunity to meet and actively participate onsite the Auditorium Friedrichstraße in Berlin will be made possible. A detailed agenda and link to registration will follow soon - we'll keep you posted!
The RegMed Forum is an open access conference, participation is free of charge.
About the event
The Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT) and the Cluster Health Capital Berlin-Brandenburg are jointly organising the international RegMed Forum since 2014.
This event series provide the opportunity to hear and discuss science in the field of regenerative medicine - from basic research to clinical implementation and industrialization. In addition to a comprehensive scientific program there will be opportunities to discuss and network with industry and research groups in the regenerative medicine field.
About BIH Center for Regenerative Medicine (BCRT)
The research landscape of Berlin/Brandenburg has developed into one of the most important international clusters for regenerative medicine. A major contribution to this development has been the BIH Center for Regenerative Therapies (BCRT) - an interdisciplinary clinical translational center operated by the Berlin Institute of Health (BIH).
The primary focus of the BCRT is the development of novel methods to promote endogenous regeneration to address acute and chronic diseases of the immune, musculoskeletal and cardiovascular systems. This includes using cells, biomaterials and biological factors or a combination thereof to provide long term and possibly even curative treatments. With respect to the development and implementation of innovative therapies and products from the BCRT, the first potential success story for a novel regenerative product is starting to emerge. Virus-specific T-cell products for long-term protection against serious infections are being evaluated in onsite clinical studies for treatment of patients with a weakened immune system. Following the concept of refined translation, i.e. iterative incorporation of (pre-) clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards clinical evaluation. This also includes new cell-based therapies for heart disease and muscle injuries.
About the Cluster Health Capital
The German capital region is one of the world's leading locations for the healthcare industry, healthcare, and the life sciences. Leading global companies, renowned scientists, first-class hospitals, innovative start-ups, and specialists from all over the world work together in Berlin-Brandenburg each day to deliver the very best goods and services for the regional and global healthcare markets.
The cluster management team at Berlin Partner for Business and Technology and Brandenburg Economic Development Corporation (WFBB) drives networking and the technology transfer in the region and supports international companies interested in relocating to the German capital region.
Compliance with Corona rules
The event will take place in compliance with the currently valid Corona rules according to the Ordinance (see here) and following the 2G Corona rule.
Due to that we only have limited space for onsite participants. Please only register for this onsite event in case you are willing to come onsite on Nov 25th.
Please note: you are obliged to wear a medical mask.
We strongly encourage everyone to perform a point-of-care (PoC) antigen test before the event; we also provide limited testing capacity on site. This will ensure maximum safety for all participants at the event.
Due to the necessary additional documentation work, the registration process will take more time than normally. You can contribute to a smooth and speedy registration by keeping at hand a document that proves your 2G status. Your proof of vaccination against or recovery from SARS-CoV-2 must be digitally verifiable and have to be compared to your photo identification.
We encourage you to document your attendance using digital applications that enable automated data collection (such as Corona- or Luca-app and the respective event QR code, will be provided at the event venue). A possibility to document attendance without using digital applications will also be provided at the venue.
Persons who cannot be vaccinated for medical reasons have to be tested negative (using a point-of-care (PoC) antigen test carried out within the last 24 hours) and have to show proof of inability to be vaccinated as certified by a physician.
Thank you in advance for respecting the current Corona regulations under 2G conditions (e.g. the so called AHA-L rules, see also here for more information).
Please don´t hesitate to contact us in case you have questions.
We are looking forward to meeting you on Thursday!
FUNDING
This project is funded by resources from the federal state of Berlin and by the european fund for regional development from the investment bank of Berlin.
Gefördert aus Mitteln des Landes Berlin und des Europäischen Fonds für regionale Entwicklung durch die Investitionsbank Berlin.
